Change in fair
value of
derivative asset - - (81) -
Other income
(expense), net (3) 922 12 964
--------- --------- --------- ---------
Loss before
provision for
income taxes (5,732) (4,912) (15,260) (16,934)
Provision for
income taxes - - - -
--------- --------- --------- ---------
Net loss
attributable to
Vaccinex, Inc.
common
stockholders $ (5,732) $ (4,912) $ (15,260) $ (16,934)
========= ========= ========= =========
Comprehensive loss $ (5,732) $ (4,912) $ (15,260) $ (16,934)
========= ========= ========= =========
Net loss per share
attributable to
Vaccinex, Inc.
common
stockholders,
basic and diluted $ (2.83) $ (15.25) $ (8.85) $ (59.95)
========= ========= ========= =========
Weighted-average
shares used in
computing net loss
per share
attributable to
Vaccinex, Inc.
common
stockholders,
basic and diluted 2,026,920 322,153 1,724,088 282,467
========= ========= ========= =========
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/551b0bc4-4495-4a65-aa21-a96daddf079e
(END) Dow Jones Newswires
November 18, 2024 08:30 ET (13:30 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。